Abelacimab by Anthos Therapeutics for Venous (Vein) Thrombosis: Likelihood of Approval

Abelacimab is under clinical development by Anthos Therapeutics and currently in Phase I for Venous (Vein) Thrombosis.

Cybin Announces Grant of Additional U.S. Patent in Support of its CYB003 Deuterated Psilocybin Analog Program | Psychedelic Invest

Newly issued patent expected to provide protection until at least 2041 and includes composition of matter claims to pharmaceutical compositions within the Company’s proprietary CYB003

December 6, 2023

New study identifies brain circuit key to reducing cocaine-seeking behavior

Imagine a future where the grip of cocaine use disorder can be loosened, where cravings fade, and the risk of relapse diminishes.

February 27, 2025

Understanding genetic mosaicism in human cells

In a study led by Jan Korbel at the European Molecular Biology Laboratory (EMBL) and Ashley Sanders at the Berlin Institute for Medical Systems Biology

May 28, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.